{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:32:42Z","timestamp":1777408362750,"version":"3.51.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/mcg.0b013e31825ceed9","type":"journal-article","created":{"date-parts":[[2012,8,31]],"date-time":"2012-08-31T06:32:54Z","timestamp":1346394774000},"page":"865-870","source":"Crossref","is-referenced-by-count":65,"title":["High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy"],"prefix":"10.1097","volume":"46","author":[{"given":"Kevin T.","family":"Chaung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nghiem B.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huy N.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruel T.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huy A.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khanh K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmet B.","family":"Keeffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210305","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"R2-18-20210305","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cld.2004.12.009","article-title":"Epidemiology of hepatocellular carcinoma.","volume":"9","author":"Bosch","year":"2005","journal-title":"Clin Liver Dis"},{"key":"R3-18-20210305","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM200205303462202","article-title":"Chronic hepatitis B.","volume":"346","author":"Lok","year":"2002","journal-title":"N Engl J Med"},{"key":"R4-18-20210305","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2105\/AJPH.89.1.14","article-title":"Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994.","volume":"89","author":"McQuillan","year":"1999","journal-title":"Am J Public Health"},{"key":"R5-18-20210305","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2008.08.021","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.","volume":"6","author":"Keeffe","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R6-18-20210305","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"R7-18-20210305","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"R8-18-20210305","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","article-title":"Risk and predictors of mortality associated with chronic hepatitis B infection.","volume":"5","author":"Iloeje","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-18-20210305","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"R10-18-20210305","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2007.03.111","article-title":"Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion.","volume":"132","author":"Ni","year":"2007","journal-title":"Gastroenterology"},{"key":"R11-18-20210305","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009.","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"R13-18-20210305","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s10620-010-1179-4","article-title":"Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection.","volume":"55","author":"Liaw","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R14-18-20210305","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"key":"R15-18-20210305","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1542-3565(03)00312-4","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.","volume":"2","author":"Keeffe","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-18-20210305","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.cgh.2006.05.016","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.","volume":"4","author":"Keeffe","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R17-18-20210305","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1440-1746.2003.03037.x","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: an update.","volume":"18","author":"Liaw","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R18-18-20210305","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1478-3231.2005.01134.x","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.","volume":"25","author":"Liaw","year":"2005","journal-title":"Liver Int"},{"key":"R19-18-20210305","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"Chronic hepatitis B.","volume":"34","author":"Lok","year":"2001","journal-title":"Hepatology"},{"key":"R20-18-20210305","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/hep.20110","article-title":"Chronic hepatitis B: update of recommendations.","volume":"39","author":"Lok","year":"2004","journal-title":"Hepatology"},{"key":"R21-18-20210305","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/j.1440-1746.2005.03952.x","article-title":"Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy.","volume":"20","author":"Byun","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"R22-18-20210305","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/jhep.2003.50117","article-title":"Durability of serologic response after lamivudine treatment of chronic hepatitis B.","volume":"37","author":"Dienstag","year":"2003","journal-title":"Hepatology"},{"key":"R23-18-20210305","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s10620-008-0508-3","article-title":"Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation.","volume":"54","author":"Kim","year":"2009","journal-title":"Dig Dis Sci"},{"key":"R24-18-20210305","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/00365520903394550","article-title":"Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion.","volume":"45","author":"Kuo","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"R25-18-20210305","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.","volume":"139","author":"Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"R26-18-20210305","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0168-8278(03)00394-5","article-title":"Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.","volume":"39","author":"Ryu","year":"2003","journal-title":"J Hepatol"},{"key":"R27-18-20210305","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/jhep.2000.16665","article-title":"Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.","volume":"32","author":"Song","year":"2000","journal-title":"Hepatology"},{"key":"R28-18-20210305","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/592570","article-title":"Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants.","volume":"47","author":"Wu","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R29-18-20210305","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcv.2009.04.006","article-title":"Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.","volume":"45","author":"Yeh","year":"2009","journal-title":"J Clin Virol"},{"key":"R30-18-20210305","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.","volume":"133","author":"Gish","year":"2007","journal-title":"Gastroenterology"},{"key":"R31-18-20210305","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3748\/wjg.14.1268","article-title":"Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.","volume":"14","author":"Lu","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R32-18-20210305","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.23568","article-title":"Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0b013e31825ceed9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:09:50Z","timestamp":1620961790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201211000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e31825ceed9","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}